Pub. Date : 2015 Aug
PMID : 25716872
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Four PFIC2 patients harboring at least one missense mutation (p.G982R, p.R1128C, and p.T1210P) were treated orally with 4-PB and followed prospectively. | 4-phenylbutyric acid | ATP binding cassette subfamily B member 11 | Homo sapiens |
| 2 | Treatment with 4-PB and UDCA partially corrected Bsep mutant targeting. | 4-phenylbutyric acid | ATP binding cassette subfamily B member 11 | Homo sapiens |
| 3 | CONCLUSION: 4-PB therapy may be efficient in selected patients with PFIC2 owing to ABCB11 missense mutations affecting BSEP canalicular targeting. | 4-phenylbutyric acid | ATP binding cassette subfamily B member 11 | Homo sapiens |
| 4 | CONCLUSION: 4-PB therapy may be efficient in selected patients with PFIC2 owing to ABCB11 missense mutations affecting BSEP canalicular targeting. | 4-phenylbutyric acid | ATP binding cassette subfamily B member 11 | Homo sapiens |
| 5 | CONCLUSION: 4-PB therapy may be efficient in selected patients with PFIC2 owing to ABCB11 missense mutations affecting BSEP canalicular targeting. | 4-phenylbutyric acid | ATP binding cassette subfamily B member 11 | Homo sapiens |
| 6 | Bile secretion improvement may be a result of the ability of 4-PB to retarget mutated BSEP. | 4-phenylbutyric acid | ATP binding cassette subfamily B member 11 | Homo sapiens |